tRF-18-8R1546D2 is upregulated in hepatocellular carcinoma and associated with poor prognosis and tumor progression Authors: Liu-Xia Yuan, Zhi-Qiang Yue, Jing-Wen Xiao, Lin-ling Ju, Hui-Xuan Wang, Jia-Jia Tan, Feng Xiao, Lin Chen Published: 2026 ABSTRACT AbstractThis study aimed to investigate the clinical significance of tRF-18-8R1546D2 in hepatocellular carcinoma and to explore its potential role in tumor progression. tRF-18-8R1546D2 was identified as a potential oncogenic factor in HCC based on PCR Array sequencing. Its expression levels and subcellular localization in HCC were examined using qRT-PCR, FISH, and nuclear-cytoplasmic RNA fractionation. ROC curve, Cox and survival analysis were performed to determine the diagnostic and prognostic value. EdU incorporation, colony formation, apoptosis and transwell assays were conducted to assess cellular functions of tRF-18-8R1546D2. KEGG and Go analysis were conducted to seek for possible pathways in HCC progression. Bioinformatics analysis was conducted to screen potential targets of tRF-18-8R1546D2. qRT-PCR and IHC were used to examine the ECM2 expression, and its association with tRF-18-8R1546D2 was examined using correlation, dual-luciferase reporter assays and rescue assays. tRF-18-8R1546D2 was upregulated in HCC tissues, cell lines and plasma, its high expression was associated with poor prognosis and early detection. Cox analysis confirmed that tRF-18-8R1546D2 was a clinically potential prognostic marker. Functional assays revealed that overexpression of tRF-18-8R1546D2 promoted cell proliferation, migration, invasion in HCC and reduced apoptosis, the knockdown of tRF-18-8R1546D2 yielded the opposite results. ECM2 was downregulated in HCC tissues and cell lines, shown a better prognostic value and enriched in EMT pathways. Finally, Bioinformatics analysis, correlation, dual-luciferase reporter assays and rescue assays shown that tRF-18-8R1546D2 may downregulate ECM2 expression. tRF-18-8R1546D2 plays an oncogenic role in HCC and may drive tumor progression through downregulation of ECM2. Importantly, tRF-18-8R1546D2 may assist HCC detection, prognosis and treatment.Keywords: tRNA fragment, ECM2, HCC, Biomarkers, Prognosis Introduction HCC is the most common primary liver cancer and remains a major cause of cancer-related death worldwide [1]. Despite recent advances in molecular targeted therapy and immunotherapy for HCC, the prognosis of patients is still unsatisfactory [2–4]. Therefore, discovering new therapeutic targets is essential for improving patient outcomes. Investigating the mechanisms and identifying molecular therapeutic targets remain a major focus of HCC research [5]. Current research in this field mainly focuses on noncoding RNAs (ncRNAs), including circular RNAs (circRNAs) [6] microRNAs (miRNAs) [7], tRNA-derived small RNAs (tsRNAs) [8], and other subtypes of noncoding RNAs. Notably, compared with other RNA molecules and proteins, tsRNAs are generated earlier during biogenesis [9]. tsRNAs are detectable in body fluids and are stably expressed [10]. Previous studies have demonstrated that circulating tRF-Pro-AGG-004 and tRF-Leu-CAG-002 are associated with early detection of pancreatic cancer [11], while higher tRF-Leu-CAG correlates with advanced stages of non-small cell lung cancer [12]. These findings support tsRNAs as potential circulating biomarkers in various cancers. tsRNAs are a newly identified group of non-coding RNAs generated from precursor or mature tRNAs through specific cleavage processes [13]. tsRNAs can be broadly classified into tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs) according to their cleavage features and fragment lengths [14]. These small RNAs contribute to various cellular processes, including signaling, gene regulation, and chromatin dynamics [15]. As reported, tsRNAs can exert oncogenic or tumor-suppressive effects in various cancers by interacting with mRNAs or proteins [16]. For instance, tRF-34-P4R8YP9LON4VHM promotes HCC progression through MEK/ERK signaling pathway [17]. 5′-tiRNA-Gln suppresses HCC development by inhibiting translation through its interaction with eIF4AI [18]. These findings highlight the biological significance of tRFs. However, the function of tRF-18-8R1546D2 in HCC pathogenesis remains to be determined. In the present work, to screen for dysregulated tsRNAs in HCC, we performed PCR Array sequencing in five paired HCC tissues and identified a novel dysregulated tRF-3, tRF-18-8R1546D2, which shows the most pronounced upregulation in HCC tissues. Clinically, the expression of tRF-18-8R1546D2 was closely associated with higher tumor stage and lymph node metastasis, and higher tRF-18-8R1546D2 shown poor survival rate. ROC analysis suggested that tRF-18-8R1546D2 may assist HCC detection. Cox analysis confirmed that tRF-18-8R1546D2 was a clinically potential prognostic marker. Further functional investigation revealed that tRF-18-8R1546D2 could regulate the expression of ECM2, promote invasion and migration of HCC cells induced by EMT. Thus, tRF-18-8R1546D2 may be a promising target for HCC treatment. Materials and methods Sample collection HCC tissue samples were collected from Nantong Third People’s Hospital. Five pairs of HCC tissues and corresponding adjacent non-tumorous samples were subjected to PCR Array sequencing to detect aberrantly expressed tsRNAs. In addition, 65 paired HCC tissues and their corresponding adjacent nontumor tissues were collected for subsequent validation analyses. Plasma samples from 80 healthy controls, 68 patients with hepatitis, 73 patients with HCC and 53 paired preoperative and postoperative plasma samples were collected for subsequent analysis. This research received approval from the Ethics Committee of Nantong Third People’s Hospital. Cell culture LO2 (normal liver cell) and HCC cell lines (PLC/PRF/5, Li-7, SK-HEP-1, HCCLM3, and Huh7) were obtained from Cell Culture Facility (Shanghai, China). LO2 and Li-7 cells were cultured in RPMI-1640 medium (Gibco, USA), PLC/PRF/5 and SK-HEP-1 cells were cultured in MEM (Gibco, USA), while HCCLM3 and Huh7 cells were cultured in DMEM (Gibco, USA). All culture media were supplemented with 10% fetal bovine serum (FBS). Cell cultures were kept at 37 °C under 5% CO₂ conditions. Quantitative Real-Time PCR (qRT-PCR) TRIzol reagent (Invitrogen, USA) was used to obtain RNA, after which its concentration and purity were measured with a NanoDrop spectrophotometer. The extracted RNA was then reverse transcribed into cDNA (Thermo Fisher Scientific, USA). Quantitative real-time PCR was carried out using SYBR Green reagents (Bio-Rad, China) with gene-specific primers (RiboBio, China). U6, 18 S, and GAPDH served as internal controls. Relative expression levels were determined using the 2^−ΔΔCt method. The PCR product was mixed with loading buffer, run at 2.5% Agarose gel for 40 min. Actinomycin D assay We seed PLC/PRF/5 and HCCLM3 cells in six-well plate overnight, 1000 ng/mL actinomycin D was added, and finally collected at designated time points (0–12 h). RNA was extracted and reverse transcribed, followed by qRT-PCR to determine the stability of tRF-18-8R1546D2. Nuclear and cytoplasmic extraction Cytoplasmic and nuclear RNA fractions were prepared using a commercial RNA purification kit (BIOTEK, Canda). Cells were harvested and lysed thoroughly with lysis buffer. Following centrifugation, the supernatant and pellet were separated. Cytoplasmic and nuclear RNA were individually bound to the column, washed three times with Wash Buffer, and then eluted and stored for further use. The distribution of tRF-18-8R1546D2 in these fractions was analyzed by qRT-PCR. Fluorescence in situ hybridization (FISH) Cy3-labeled probes targeting tRF-18-8R1546D2 and 18S were purchased from Gene-Pharma (Shanghai, China). RNA fluorescence in situ hybridization (FISH) was carried out, including pre-hybridization, hybridization, and subsequent blocking steps. After hybridization, nuclei were visualized by DAPI staining and images were acquired using a fluorescence microscope. Construction and transfection of vectors The tRF-18-8R1546D2 mimics and inhibitors were purchased by RiboBio (Guangzhou, China). Cells were transfected using a RiboBio transfection reagent kit. The ECM2 overexpression plasmid was constructed by Gene-Pharma (Shanghai, China) and transfected by Lipofectamine 3000 (Invitrogen, USA). 5-Ethynyl-20-Deoxyuridine (EdU) incorporation assay After transfection, the cells were collected and resuspended in complete culture medium, and 2,000 cells were seeded into 96-well plates and detected using an EdU detection kit (Beyotime, China). Cells were incubated with EdU working solution for 3 h. The supernatant was removed, and cells were fixed with paraformaldehyde for 15 min. After washing with PBS, cells were incubated with 0.3% Triton X-100 in PBS for 15 min, followed by three PBS washes. Then, 50 µL of Click reaction solution was added to each well and incubated in the dark for 30 min. After PBS washing, cells were stained with Hoechst 33,342 for 10 min in the dark. Finally, after PBS washing, fluorescence detection was performed. Colony formation assay A total of 3,000 cells were seeded and cultured for one week. Colonies were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and visualized under a light microscope. Colonies were counted for analysis. Invasion and migration assay Transfected cells were prepared in serum-free MEM at a concentration of 1 × 10⁵ cells, MEM containing 20% FBS was added into lower plate. Migration assays were performed using uncoated chambers, while invasion assays were conducted with Matrigel-coated chambers, into which cells were subsequently seeded. After incubation for 48 h, cells were fixed, stained, and visualized under a light microscope. Apoptosis assay After transfection, the cells were resuspended in binding buffer and incubated with Annexin V and 7-AAD (BD Biosciences, USA) for 15 min. Binding buffer was added to stop the reaction, the samples were analyzed by flow cytometry to determine the proportion of apoptotic cells. Western blot analysis Cells were lysed in RIPA buffer (Beyotime, China) with PMSF and protease inhibitors. Proteins were separated by SDS-PAGE, transferred onto PVDF membranes, and detected using an ECL system (Tanon, China). Primary antibodies against β-actin, E-cadherin, vimentin, N-cadherin, and GAPDH were used (Proteintech, China), with secondary antibodies obtained from Beyotime (Shanghai, China). Immunohistochemistry (IHC) examination Deparaffinization was performed with xylene, followed by rehydration through a graded ethanol series. Antigen retrieval was carried out using citrate buffer, and endogenous peroxidase activity was blocked with 3% H₂O₂ for 30 min. The sections were incubated with anti-ECM2 primary antibody (1:100) at 4 °C overnight, followed by incubation with HRP-conjugated anti-rabbit secondary antibody (1:1000) at room temperature for 1 h. After washing, the sections were stained with hematoxylin and 3,3′-diaminobenzidine (DAB, China). Dual-luciferase reporter assay Dual-luciferase reporter assays were performed by co-transfecting wild-type or mutant reporter plasmids together with tRF-18-8R1546D2 mimic or corresponding negative controls. After 48 h of transfection, luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, USA). Firefly luciferase activity was normalized to Renilla luciferase activity. Survival analysis Patients with available follow-up information were included in the survival analysis. Patients were divided into high- and low-expression groups according to the median expression level of tRF-18-8R1546D2. Overall survival (OS) was analyzed using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were performed to evaluate prognostic factors. The proportional hazards assumption was assessed using Schoenfeld residuals. Statistical analysis All data are presented as mean ± SD. Statistical analyses were performed using GraphPad Prism 8.0 or SPSS 17.0 software. Student’s t-test was used for two-group comparisons, and one-way ANOVA was applied for multiple-group comparisons. A p value of less than 0.05 was considered statistically significant. Results Increased tRF-18-8R1546D2 was related to poor prognosis in HCC tissues To screen for tRFs related to HCC progression, we performed PCR Array sequencing using five paired HCC and adjacent nontumor tissues. Correlation analysis revealed distinct molecular differences between the two tissue groups (Fig. 1A). Differential expression analysis revealed several significantly dysregulated tRFs, among which we selected the most significantly upregulated tRF, tRF-18-8R1546D2, for further analysis (Fig. 1B-D). qRT-PCR analysis confirmed that tRF-18-8R1546D2 was overexpressed in HCC tissues (Fig. 1E). Higher tRF-18-8R1546D2 was associated with poor survival in HCC patients (Fig. 1F). Moreover, tRF-18-8R1546D2 was related to tumor stage (p = 0.033) and lymph node metastasis (p = 0.039) (Table 1). Univariate Cox regression revealed that tRF-18-8R1546D2 expression (p = 0.024) and TNM stage (p = 0.024) were risk factors for HCC. Multivariable analysis confirmed that tRF-18-8R1546D2 expression (p = 0.050) was a potential prognostic indicator for HCC (Table 2). Thus, tRF-18-8R1546D2 is a good prognostic marker for HCC. tRF-18-8R1546D2 was highly expressed in HCC tissues. A Correlation coefficient of the two samples. B Up-regulated and down-regulated tsRNAs were shown in the volcano plot. C Heatmap of the differentially expressed tsRNAs. D The Log2FC of significantly differentially expressed tsRNAs. E The high expression level of tRF-18-8R1546D2 was confirmed in 65 pairs of HCC tissues. F Kaplan–Meier survival curve analysis based on the tissues tRF-18-8R1546D2 expression levels of HCC patients. *p < 0.05, **p < 0.01, ***p < 0.001 Table 1The clinicopathological parameters of HCC patients AFP: alpha fetoprotein; P-value ≤ 0.05 indicate statistical significanceClinicopathologicalcharacteristicstRF-18-8R1546D2 expressionP valueLow expressionHigh expressionAge(years)0.062≥ 6020 (62.5%)13 (39.4%)< 6012 (37.5%)20 (60.6%)Gender0.321Female8 (25%)5 (15.2%)Male24 (75%)28 (84.8%)AFP (ng/mL)0.536≥ 6017 (53.1%)15 (45.5%)< 6015 (46.9%)18 (54.5%)Tumor size (cm)0.531≥ 418 (56.2%)16 (48.5%)< 414 (43.8%)17 (51.5%)Tumor stage0.033I-II17 (53.1%)9 (27.3%)II-IV15 (46.9%)24 (72.7%)Lymph node metastasis0.039No26 (81.2%)19 (57.6%)Yes6 (18.8%)14 (42.4%) The clinicopathological parameters of HCC patients AFP: alpha fetoprotein; P-value ≤ 0.05 indicate statistical significance Table 2Univariable and multivariable Cox regression analysis for overall survival in HCCIndexUnivariableMultivariableP valueHazard ratio95% Clfor Exp (B)P valueHazard ratio95% Clfor Exp (B)tRF-18-8R1546D20.0243.2481.165–9.0470.0502.8081.001–7.876Gender0.1770.4901.174–1.381Age0.3990.6750.271–1.682TNM Stage0.0243.5761.183–10.8050.0463.1061.019–9.462AFP0.8020.8990.360–2.247Lymph node metastasis0.0782.2580.914–5.579Tumor size0.5041.3610.551–3.358 Univariable and multivariable Cox regression analysis for overall survival in HCC Expression and diagnostic value of tRF-18-8R1546D2 in HCC plasma tRF-18-8R1546D2 were elevated in HCC and hepatitis patients compared with healthy controls (Fig. 2A). Higher tRF-18-8R1546D2 expression was associated with advanced TNM stage (Fig. 2B) and lymph node metastasis (Fig. 2C). Furthermore, the tRF-18-8R1546D2 expression was significantly decreased after surgery (Fig. 2D). ROC analysis revealed that tRF-18-8R1546D2 could distinguish HCC patients from healthy controls, the AUC of tRF-18-8R1546D2 was 0.7664 (95% CI: 0.672–0.852), and the area of AFP was 0.743 (95% CI: 0.608–0.877) (Fig. 2E). These results suggest that tRF-18-8R1546D2 shows a good value for HCC diagnosis. Expression and diagnostic value of tRF-18-8R1546D2 in clinical sample. A Scatter plot of tRF-18-8R1546D2 levels in plasma from healthy controls, Hepatitis patients and HCC patients. B Scatter plot of tRF-18-8R1546D2 levels in plasma from healthy controls, HCC patients (Stage I-II) and HCC patients (Stage III-IV). C Scatter plot of tRF-18-8R1546D2 levels in plasma from healthy controls, HCC patients (M0) and HCC patients (M1). D Expression levels in Pre-operation and post-operation plasma. E ROC curve analysis of tRF-18-8R1546D2 expression and AFP value. *p < 0.05, **p < 0.01, ***p < 0.001 tRF-18-8R1546D2 located in cytoplasm and exhibited high stability On the basis of the MINTbase v2.0 dataset, we determined that tRF-18-8R1546D2 is a type of 3’ end tRF with the sequence 5’-TCCCCAGTACCTCCACCCA-3’ (Fig. 3A). tRF-18-8R1546D2 is generated from the T-loop region of tRNA-Ala-AGC-1-1 (Fig. 3B). Melting and amplification curves confirmed the successful detection of tRF-18-8R1546D2 (Fig. 3C). Agarose gel electrophoresis and sanger sequencing confirmed the obtained sequence in the MINTbase v2.0 database (Fig. 3D-E). Subcellular localization analysis using FISH showed that tRF-18-8R1546D2 is predominantly distributed in the cytoplasm (Fig. 3F). Additionally, quantification of nuclear and cytoplasmic RNA indicated that tRF-18-8R1546D2 is more enriched in the cytoplasm (Fig. 3G). To assess its stability, we conducted an actinomycin D assay, which revealed that tRF-18-8R1546D2 is stable in HCC cell lines (Fig. 3H). Thus, tRF-18-8R1546D2 can serve as a detection biomarker. The characteristic of tRF-18-8R1546D2. A tRF-18-8R1546D2 was derived from tRNA-Ala-AGC-1-1 at MINTbase datasets. B The arrow points of tRF-18-8R1546D2 to the cutting position. C Gel electrophoresis of the RT-PCR products was performed. D The qRT-PCR product of tRF-18-8R1546D2 was verified by Sanger sequencing. E Fish assay was performed to observed the location of tRF-18-8R1546D2 in PLC/PRF/5 and HCCLM3 cell lines. F Nucleocytoplasmic separation assay in PLC/PRF/5 and HCCLM3 cell lines. G The RNA expression of tRF-18-8R1546D2 in HCC cells was analyzed by qRT-PCR after treatment with Actinomycin D assay in PLC/PRF/5 and HCCLM3 cell lines. *p < 0.05, **p < 0.01, ***p < 0.001 Knockdown of tRF-18-8R1546D2 inhibits the migration, invasion and proliferation of HCC cell lines Next, qRT-PCR revealed that tRF-18-8R1546D2 was overexpressed in HCC cells (Fig. 4A). To explore the function of tRF-18-8R1546D2, we transfected a tRF-18- Knockdown of tRF-18-8R1546D2 inhibits the migration, invasion and proliferation of HCC cell lines. A tRF-18-8R1546D2 expression level in HCC cell lines. B-C The knockdown efficiency in PLC/PRF/5 and SK-HEP-1. D-E EDU assay in PLC/PRF/5 and SK-HEP-1. F-G Colony formation assay in PLC/PRF/5 and SK-HEP-1. H Transwell assays in PLC/PRF/5. I Transwell assays in SK-HEP-1. J Cell apoptosis in PLC/PRF/5. K Cell apoptosis in SK-HEP-1. *p < 0.05, **p < 0.01, ***p < 0.001 8R1546D2 inhibitor or NC inhibitor into PLC/PRF/5 and SK-HEP1 cells. The knockdown efficiency was confirmed by qRT‒PCR (Fig. 4B-C). DNA synthesis levels were measured using an EdU assay, which revealed a significant decrease in tRF-18-8R1546D2-inhibited cells compared with control cells (Fig. 4D-E). A notable decrease in colony formation was observed in PLC/PRF/5 and SK-HEP1 cells following tRF-18-8R1546D2 knockdown (Fig. 4F–G). A reduction in migration and invasion was observed in PLC/PRF/5 and SK-HEP1 cells following tRF-18-8R1546D2 knockdown (Fig. 4H-I). Furthermore, inhibition of tRF-18-8R1546D2 increased the apoptosis rate, as determined by flow cytometry (Fig. 4J-K). Overexpression of tRF-18-8R1546D2 enhances the migration, invasion and proliferation of HCC cell lines tRF-18-8R1546D2 mimics and NC mimics were transfected into HCCLM3 cells (Fig. 5A). Through EdU and colony formation assays, increased proliferation was observed in response to tRF-18-8R1546D2 overexpression (Fig. 5B–D). Transwell assays further demonstrated increased migration and invasion abilities (Fig. 5E–F), while flow cytometry indicated reduced apoptosis (Fig. 5G). Overexpression of tRF-18-8R1546D2 promotes the migration, invasion and proliferation of HCC cell lines. A The overexpression efficiency in HCCLM3. B-C EDU assay in HCCLM3. D Colony formation assay in HCCLM3. E Migration assays in HCCLM3. F Invasion assays in HCCLM3. G Cell apoptosis in HCCLM3. *p < 0.05, **p < 0.01, ***p < 0.001 tRF-18-8R1546D2 could promote HCC progression through EMT pathways To investigate the influence of tRF-18-8R1546D2 in HCC progression, transcriptome analysis was carried out. Hierarchical clustering showed a clear separation between the tRF-18-8R1546D2 inhibitor and negative control groups, with good consistency among biological replicates (Fig. 6A). A total of 84 genes showed significant differential expression, including 46 upregulated genes (Fig. 6B). GO analysis revealed that these genes were enriched in signal transduction, cell proliferation, and migration, and were mainly involved in mRNA and protein binding (Fig. 6C). KEGG pathway analysis further indicated that these genes were significantly enriched in tumor-related pathways, including pathways in cancer, focal adhesion and ECM-receptor interaction pathway (Fig. 6D). Consistently, reduced tRF-18-8R1546D2 levels were associated with elevated E-cadherin expression and decreased vimentin expression, while overexpressed tRF-18-8R1546D2 levels yield the opposite results, suggesting that tRF-18-8R1546D2 regulates HCC progression through EMT (Fig. 6E). tRF-18-8R1546D2 could promote HCC progression through EMT pathways. A Cluster heat map of the DEGs between tRF-18-8R1546D2-knockdown and negative control. B Volcano plot showing significant DEGs between the tRF-18-8R1546D2-knockdown and negative control. C-D Go and KEGG analysis in tRF-18-8R1546D2-related genes. E Western blot analysis of EMT key proteins Tumor suppressor ECM2 predicts favorable prognosis and is regulated by tRF-18-8R1546D2 Bioinformatic analysis predicted a potential binding site between tRF-18-8R1546D2 and the 3’UTR of ECM2 mRNA (Fig. 7A). Based on Timer and GEPIA datasets, we found ECM2 was low expressed in HCC tissues (Fig. 7B-C). Next, qRT-PCR revealed that ECM2 was downregulated in HCC tissues and cell lines (Fig. 7D-E). IHC results shown that ECM2 located in extracellular and downregulated in HCC tissues (Fig. 7F). Survival analysis shown that high ECM2 expression exhibited significantly better overall survival (Fig. 7G) and Disease-Specific Survival (Fig. 7H). What’s more, ECM2 was enriched in EMT pathways (Fig. 7I). There is a negative correlation between ECM2 and tRF-18-8R1546D2 (Fig. 7J). Moreover, ECM2 mRNA levels were decreased following tRF-18-8R1546D2 overexpression, but increased upon its inhibition (Fig. 7K-L). Luciferase activity of the ECM2-WT reporter was significantly inhibited by tRF-18-8R1546D2 mimics, whereas no significant change was detected in the ECM2-Mut construct (Fig. 7M). We performed overexpression assays and verified the efficiency by qRT-PCR (Fig. 7N). Rescue experiments further demonstrated that the increased migration and invasion cell numbers driven by tRF-18-8R1546D2 mimics were partially abolished upon ECM2 overexpression in HCC cells. (Fig. 7O). Collectively, these results suggest that tRF-18-8R1546D2 could regulate ECM2 expression. Tumor suppressor ECM2 predicts favorable prognosis and is regulated by tRF-18-8R1546D2. A Prediciton of binding sites between tRF-18-8R1546D2 and ECM2. B-C ECM2 expression based on Timer and GEPIA datasets. D-E The Low expression level of ECM2 was confirmed in 60 pairs of HCC tissues and cell lines. F The Low expression level of ECM2 was determined by IHC analysis. G The OS survival was drawn by KM Plot. H The DSS was drawn by KM Plot. I The GSEA analysis enrich in EMT. J Correlation analysis between ECM2 and tRF-18-8R1546D2 expression levels in HCC tissues. K-L The relative expression of ECM2 expression in HCC cells transfected with tRF-in or tRF-mi was measured by qRT-PCR. M Dual-luciferase reporter assays were performed by co-transfecting wild-type or mutant reporter plasmids together with tRF-18-8R1546D2 mimic or corresponding negative controls. N The overexpression efficiency of ECM2. O Transwell assay was used to detect the ability of invasion and migration of HCC cells transfected with NC-mi + oe-NC, NC-mi + oe-ECM2, tRF-mi + oe-NC and tRF-mi + oe-ECM2. *p < 0.05, **p < 0.01, ***p < 0.001 Discussion HCC, the main type of primary liver cancer, remains a major global health burden with high mortality and heterogeneous etiologies [19]. Due to late diagnosis and limited effective early detection, there is a pressing need to improve diagnostic approaches and patient prognosis [20].tRFs are involved in various diseases, especially in cancer progression [21]. For instance, tRF-Tyr was shown to inhibit GC progression by targeting hnRNPD [22].Similarly, tRF-Pro-CGG was significantly decreased and acted as an independent prognostic factor in PDAC [23]. Moreover, tRF-Gly-CCC-012 reduces the ubiquitination and degradation of PHGDH, leading to enhanced progression of pancreatic cancer [24]. Although recent studies have reported that tRF-18-8R1546D2 is aberrantly expressed in lung cancer and colorectal cancer [25, 26], its role in hepatocellular carcinoma remains largely unexplored. In this study, firstly, tRF-18-8R1546D2 was upregulated in HCC tissues, correlated with higher tumor stage and lymph node metastasis. Survival analysis indicated that increased tRF-18-8R1546D2 expression was linked to poorer prognosis. Cox regression analysis identified tRF-18-8R1546D2 expression as a potential prognostic indicator for HCC. Secondly, in plasma, tRF-18-8R1546D2 was highly expressed in Hepatitis and HCC patients, and the expression was significantly decreased after surgery, suggesting a potential diagnostic value according to ROC analysis. Thirdly, tRF-18-8R1546D2 was also highly expressed in HCC cell lines. tRF-18-8R1546D2 derived from tRNA-Ala-AGC-1-1, located in cytoplasm and had good stability. We performed functionally experiments in HCC cell lines, knockdown of tRF-18-8R1546D2 inhibited HCC malignant behaviors, while its overexpression had the opposite effect. Mechanistically, tRF-18-8R1546D2 may function as an oncogenic role by regulating EMT pathway, showing decreased E-cadherin and increased vimentin expression. These findings are in line with previous reports in colorectal cancer [26]. Extracellular matrix (ECM) contributes to tumor development by regulating cell proliferation, invasion, epithelial–mesenchymal transition (EMT), and the tumor immune microenvironment [27, 28]. Various ECM-related proteins have been reported to play important regulatory roles in tumor progression and may serve as potential prognostic biomarkers [29, 30]. Extracellular matrix protein 2 (ECM2) is a key component of ECM, has been shown act as a biomarker and prognostic indicator for LGG and glioma [31, 32], In our study, based on public datasets, qRT-PCR and IHC analysis, ECM2 were significantly decreased in HCC tissues and cell lines, and higher ECM2 expression shown a better prognosis. tRFs could regulate gene expression in a miRNA-like manner at the post-transcriptional level and have been implicated in tumor progression [33, 34]. In this study, bioinformatics analysis and dual-luciferase reporter assays revealed that tRF-18-8R1546D2 could bind to complementary sites within the 3’UTR of ECM2 mRNA. Overexpression of tRF-18-8R1546D2 was found to suppress ECM2 expression in HCC cell lines, and inhibition of tRF-18-8R1546D2 yield the overexpression of ECM2. Correlation analysis shown a negatively correlation between ECM2 and tRF-18-8R1546D2. Moreover, overexpression of ECM2 partially reversed the phenotypic changes driven by tRF-18-8R1546D2 in transwell assays, indicating a direct functional link. Several limitations of this study should be acknowledged. First, the sample size was relatively limited, independent external validation cohorts are still required to further confirm the diagnostic and prognostic value of tRF-18-8R1546D2 in HCC. Second, although tRF-18-8R1546D2 was significantly elevated in HCC patients, increased expression was also observed in hepatitis patients, which may limit its diagnostic specificity for HCC. Third, the present study mainly focused on in vitro functional experiments, and in vivo studies are still needed to further validate the biological role of tRF-18-8R1546D2 in HCC progression. Despite these limitations, our findings suggest that tRF-18-8R1546D2 may serve as a potential biomarker and functional regulator in HCC. In conclusion, tRF-18-8R1546D2 was highly expressed in HCC, correlated with poor prognosis and early detection. tRF-18-8R1546D2 could regulate ECM2 expression through EMT pathways during tumor progression. These findings reveal a novel tRF-18-8R1546D2/ECM2 regulatory axis and offer a new mechanistic perspective on HCC progression. Conclusions tRF-18-8R1546D2 promoted progression and metastasis of HCC through ECM2. Regulating tRF-18-8R1546D2/ECM2would be a potential strategy for HCC. Acknowledgements Not applicable. Author contributions Lin Chen revised the manuscript and was in charge of the final approval of the manuscript. Liu-Xia Yuan, Zhi-Qiang Yue drafted the manuscript and prepared the figures and tables. Liu-Xia Yuan, Zhi-Qiang Yue, Lin-ling Ju, Jia-Jia Tan, and Hui-Xuan Wang conducted the investigation and validation. Feng Xiao and Jing-Wen Xiao collected fresh samples and data curation. All authors reviewing and editing the manuscript, and contributed to the article and approved the submitted version. Funding This study was supported by the Nantong Science and Technology Bureau (grant no. JC2023108, MS2024009), the Health Commission of Jiangsu Province (grant no. MQ2024047), Nantong University Special Research Fund for Clinical Medicine (grant no. 2024JQ038) and Nantong Municipal Health Commission (grant nos. QN2024036, QN2024038, QNZ2024055). Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Ethics approval This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the institutional Ethics Committee of the Affiliated Nantong Hospital 3 of Nantong University (approval number: EK2022023). Consent to participate Informed consents were obtained from the participants. Consent to publish Not applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Liu-Xia Yuan and Zhi-Qiang Yue contributed equally to this work Change history 7/25/2026 The original online version of this article was revised: due to the missing equal contribution in the article. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.